- Home
- SAFE vs CGEM Comparison
SAFE vs CGEM Comparison
Compare SAFE & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAFE | CGEM |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.4B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SAFE | CGEM |
|---|---|---|
| Price | $15.52 | $22.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $19.00 | ★ $30.13 |
| AVG Volume (30 Days) | 251.8K | ★ 667.6K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ 7.43 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $385,552,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.31 | $5.20 |
| P/E Ratio | $18.94 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $12.76 | $5.68 |
| 52 Week High | $17.45 | $22.54 |
Technical Indicators
Market Signals| Indicator | SAFE | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 70.66 |
| Support Level | $14.76 | $16.40 |
| Resistance Level | $16.43 | N/A |
| Average True Range (ATR) | 0.35 | 1.16 |
| MACD | -0.00 | 0.27 |
| Stochastic Oscillator | 48.72 | 92.97 |
Price Performance
Historical ComparisonAbout SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.